City of Hope Rancho Cucamonga

Rancho Cucamonga, California 91730

0 studies enrolling now · 18 studies all time

What they study most

ATM Gene Mutation, ATR Gene Mutation, Androgen Receptor Positive, BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, Breast Cancer, CHEK1 Gene Mutation, CHEK2 Gene Mutation, Estrogen Receptor Negative, Estrogen Receptor Positive

Studies at this site

• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers — Running, not enrolling
• White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA — Paused
• Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer — Running, not enrolling
• S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer — Running, not enrolling
• Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery — Running, not enrolling
• Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease — Running, not enrolling
• Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery — Completed
• Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer — Completed
• Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer — Completed
• Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer — Completed
• Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer — Completed
• Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer — Completed
• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer — Completed
• Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer — Completed
• Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer — Completed
• Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer — Completed
• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches — Completed
• FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer — Stopped early